FY2028 EPS Estimates for Nuvectis Pharma, Inc. (NASDAQ:NVCT) Increased by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCTFree Report) – Roth Capital increased their FY2028 earnings per share estimates for shares of Nuvectis Pharma in a research report issued on Thursday, March 14th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of $3.59 for the year, up from their previous estimate of $3.57. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.59) per share.

Nuvectis Pharma Price Performance

NASDAQ NVCT opened at $8.77 on Monday. Nuvectis Pharma has a one year low of $6.20 and a one year high of $18.65. The business has a 50 day simple moving average of $8.39 and a 200 day simple moving average of $9.44. The stock has a market capitalization of $155.83 million, a P/E ratio of -6.13 and a beta of 0.34.

Insider Buying and Selling at Nuvectis Pharma

In other Nuvectis Pharma news, CEO Ron Bentsur acquired 5,000 shares of the stock in a transaction on Monday, March 18th. The shares were purchased at an average price of $10.29 per share, for a total transaction of $51,450.00. Following the completion of the acquisition, the chief executive officer now owns 3,242,484 shares in the company, valued at approximately $33,365,160.36. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 38.85% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NVCT. Tower Research Capital LLC TRC boosted its stake in Nuvectis Pharma by 216.8% in the third quarter. Tower Research Capital LLC TRC now owns 4,052 shares of the company’s stock valued at $29,000 after acquiring an additional 2,773 shares during the last quarter. Citigroup Inc. bought a new stake in Nuvectis Pharma in the 2nd quarter valued at about $33,000. California State Teachers Retirement System purchased a new stake in Nuvectis Pharma during the second quarter valued at about $36,000. Royal Bank of Canada bought a new position in Nuvectis Pharma during the second quarter worth about $43,000. Finally, Wells Fargo & Company MN increased its stake in shares of Nuvectis Pharma by 11,280.0% in the second quarter. Wells Fargo & Company MN now owns 2,845 shares of the company’s stock worth $45,000 after purchasing an additional 2,820 shares in the last quarter. Hedge funds and other institutional investors own 7.27% of the company’s stock.

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases.

See Also

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.